Eli Lilly is expanding testing of its oral GLP-1 pill, orforglipron, into two new Phase 3 trials that reach beyond its original diabetes use. One trial targets leg artery disease, and the other studies diabetes patients who fast during Ramadan. Neither trial means the drug is approved or available for these new purposes yet. For readers following GLP-1 developments, these trials show how many different conditions a single medication can be tested against before it ever reaches a pharmacy shelf.
Eli Lilly is recruiting a Phase 3 trial testing its oral GLP-1 pill for leg artery disease. This is a later stage trial, which means the company has already gathered earlier safety data and is now testing the drug in a larger group of participants. The trial's focus marks a departure from the diabetes and weight management uses most people associate with GLP-1 medications, and it points to how far pharmaceutical companies are willing to test a single drug's reach. Even so, the trial is still recruiting, and no results are available yet. The drug is not approved or available for leg artery disease, and it will not be until the trial finishes and regulators review the data.
A separate Phase 3 trial will study Eli Lilly's GLP-1 pill in diabetes patients who fast during Ramadan. Fasting changes when and how people eat, which can affect how diabetes medications work and how blood sugar responds throughout the day. Testing orforglipron under these conditions suggests Eli Lilly wants data on how the pill performs for patients who follow a fasting schedule, rather than assuming standard dosing guidance applies. This trial, like the leg artery disease study, is still recruiting participants. Results will take time, and any findings would need FDA review before doctors could use them to guide prescribing for patients who fast during Ramadan.
For now, neither trial changes what is available at the pharmacy. Both studies are still recruiting, and their outcomes are likely years away from influencing prescribing guidelines or FDA approval. If you have type 2 diabetes and fast during Ramadan, or if you live with leg artery disease, ask your doctor how your current treatment plan addresses these specific concerns rather than waiting on a future pill. And if you want to track how these trials progress, GLP1Laws will continue to follow both records as new details become available.
Key details
Eli Lilly is recruiting a Phase 3 trial testing its oral GLP-1 pill for leg artery…
A separate Phase 3 trial will study Eli Lilly's GLP-1 pill in diabetes patients who fast…
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-20